-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IhCnwd1f6NXyXzKOEijypQYtGoZcLYdNTzT3eo1qsaHYwtcRdsC2iGsavmHQZ/u+
 mwdVR6Pwjh+SEcopTFPE+Q==

<SEC-DOCUMENT>0001297077-07-000031.txt : 20070816
<SEC-HEADER>0001297077-07-000031.hdr.sgml : 20070816
<ACCEPTANCE-DATETIME>20070816161551
ACCESSION NUMBER:		0001297077-07-000031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070813
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070816
DATE AS OF CHANGE:		20070816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-EATING & DRINKING PLACES [5810]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		071062707

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cbi8k_sidransky-08162007.htm
<DESCRIPTION>8K
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>UNITED STATES</title>
</head>

<body >
<ul>
</ul>

<p>
<p align="center">
<b>UNITED STATES</b><br><b>SECURITIES AND EXCHANGE
COMMISSION</b><br><b>Washington, D.C. 20549</b><p align="center">
<b>FORM 8-K</b><p align="center">
<b>CURRENT REPORT</b><br><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b><p align="center">
<font size="2">Date of Report (Date of earliest event
reported)</font><br><font size="2">August 13, 2007</font><p align="center">
<b>CHAMPIONS BIOTECHNOLOGY, INC</b>.<br><font size="2">(Exact name of registrant
as specified in its charter)</font></p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Delaware</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">0-17263</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">52-1401755</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(State of other jurisdiction</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Commission</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(IRS Employer</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">of incorporation)</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">File Number)</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Identification No.)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">2200 Wilson Blvd.</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Suite 102-316</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Arlington, VA</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p>
<font size="2">22201</font></p>
</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Address of principal executive
offices)</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Zip Code)</font></p align="center">
</td>
</tr>
</table></div>
<p>
<p align="center">
<font size="2">Registrant&#8217;s telephone number, including area code: (703)
526-0400</font><p align="center">
<font size="2">(Former name or former address, if changed since last
report.)</font><p>
<font size="2">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</font><p>
<font size="2">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</font><br><font size="2">[&nbsp;&nbsp;]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font><p>
<b>Item 5.02 &nbsp;Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers</b><p>
Champions Biotechnology, Inc., (the &#8220;Company&#8221;) announced on
August&nbsp;14th, 2007 that Dr. David Sidransky, age 47, has been appointed to
serve on the Company&#8217;s Board of Directors. Since 1994, Dr. David Sidransky
has been the Director of the Head and Neck Cancer Research Division at Johns
Hopkins University School of Medicine, Baltimore, Maryland. He is a Professor of
Oncology, Otolaryngology, Cellular &amp; Molecular Medicine, Urology, Genetics,
and Pathology at John Hopkins University and Hospital. Dr. Sidransky is
certified in Internal Medicine and Medical Oncology by the American Board of
Medicine. Dr. Sidransky has served as Vice Chairman of the Board of Directors,
and presently is a director of ImClone. He is a Vice Chairman of Alfacell and
serves on the Board of Directors of Xenomics. He is serving and has served on
scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a
Johnson &amp; Johnson diagnostic company), among others.  <p>
The text of the related press release, which is attached as Exhibit&nbsp;99.1,
is incorporated by reference herein in its entirety.<p>
<!--<a name="_Toc147111982"></a>--><font size="2"><b>Item 9.01. Financial Statements
and Exhibits</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
release August 14, 2007</font><p align="center">
<font size="2"><b>SIGNATURES</b></font></p>
&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.	<p>
</p>
<div style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
<p>
<font size="2">Date: August 16, 2007</font></p>
</td>
<td width="277.333264" colspan="2" rowspan="1" >
<p>
<font size="2">CHAMPIONS BIOTECHNOLOGY, INC.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="3" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">By:</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2"><u>/s/&nbsp;&nbsp;James Martell</u></font></p>
</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James Martell</font></p>
</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and
President</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b></b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>cbi_sidransky-pressrel081407.htm
<DESCRIPTION>PRESS RELEASE 08-14-2007
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>  CHAMPIONS  Biotechnology, Inc</title>
</head>

<body >
<ul>
</ul>

<p align="right">
Exhibit 99.1<p align="center">
<font face="Eras Demi ITC" size="5" color="#ff0000">CHAMPIONS  Biotechnology,
Inc.</font><br><font face="Eras Demi ITC">2200 Wilson Boulevard, Suite
102-316</font><br><font face="Eras Demi ITC">Arlington, VA 22201,
USA</font><p align="center">
<font size="4"><b>Dr. David Sidransky Appointed Director of Champions
Biotechnology, Inc. </b></font><p>
Arlington, VA., August 14, 2007. Champions Biotechnology, Inc. (OTC Bulletin
Board: CSBR), a development stage biotechnology company, announced today the
appointment of Dr. David Sidransky, Director of the Head and Neck Cancer
Research Division at Johns Hopkins University School of Medicine, to serve on
the Company&#8217;s Board of Directors. Dr. Sidransky is the largest shareholder
of Champions Biotechnology.<p>
Dr. Sidransky, 47, is a renowned oncologist and research scientist named and
profiled by TIME magazine in 2001 as one of the top physicians and scientists in
America, recognized for his work with early detection of cancer. Dr. Sidransky
is one of the five most highly cited researchers in clinical and medical
journals in the world, in the field of oncology during the past decade, with
over 300 peer-reviewed publications. He has contributed more than 40 cancer
reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology
companies and holds numerous biotechnology patents.<p>
Dr. Sidransky has served as Vice Chairman of the Board of Directors, and
presently is a director of ImClone (IMCL). He is a Vice Chairman of Alfacell
(ACEL) and serves on the Board of Directors of Xenomics (XNOM). He is serving
and has served on scientific advisory boards of MedImmune (MEDI), Roche, Amgen
(AMGN) and Veridex, LLC (a Johnson &amp; Johnson diagnostic company), among
others.  <p>
Dr. Sidransky serves as Director (2005-2008) of American Association for Cancer
Research (AACR).  He was the chairperson of the first (September 2006) and is
the chairperson of the second (September 2007) AACR International Conference on
Molecular Diagnostics in Cancer Therapeutic Development: <i>Maximizing
Opportunities for Individualized Treatment</i>. <p>
Dr. Sidransky is the recipient of a number of awards and honors, including the
1997 Sarstedt International Prize from the German Society of Clinical Chemistry,
the 1998 Alton Ochsner Award Relating Smoking and Health by the American College
of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the
American Association of Cancer Research.<p>
"We are very pleased and delighted to announce that Dr. David Sidransky has been
appointed to serve as a Director of the Company&#8221; said James Martell,
Chairman, CEO and President of Champions Biotechnology. &#8220;Dr. Sidransky is
a creative, out-of-the box thinker with wide-ranging academic and business
background and extensive contacts with the pharmaceutical industry, academia and
government. His depth and breadth of experience will be invaluable to us."<p>
<p>
Champions Biotechnology is actively engaged in pursuit of additional
opportunities to grow and strengthen the company.</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>1</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>About Champions Biotechnology, Inc.
</i><p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology is a twenty
two year old publicly traded company that beginning in January 2007, changed its
business direction to focus on biotechnology. The Company is engaged in the
acquisition and early stage development of a portfolio of new therapeutic drug
candidates, in the acquisition and development of novel technologies and in
providing administrative services in the field of oncology that the Company
hopes will improve methods of and approaches to disease treatment.  <p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology plans to
develop a portfolio of new therapeutic drug candidates through pre-clinical
trials and possibly early phase ("first in man") clinical trials.  If
therapeutic drug candidates reach this early stage of development, Champions
Biotechnology intends to partner with, sell or license them to pharmaceutical
and/or biotechnology companies, as appropriate. Management believes this
strategy will enable Champions Biotechnology to leverage the competencies of
these partners or licensees to maximize Champions Biotechnology&#8217;s return
on investment in a relatively short time frame. Champions Biotechnology believes
that this model is unlike that of typical new biotechnology companies that look
to bring the process of drug development through all phases of discovery,
development, regulatory approvals, and marketing, which requires a very large
financial commitment and a long time, typically more than a decade, to
realize.<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2007, Champions
Biotechnology acquired the patent rights to two Benzoylphenylurea (BPU) sulfur
analog compounds that have shown promising potent activity against prostate and
pancreatic cancer cell lines. <p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2007, Champions Biotechnology
acquired Biomerk Inc. a company focused on generating a novel preclinical
platform of human cancer tumor immune-deficient mice xenografts (Biomerk
Tumorgrafts&#8482;).  Biomerk Tumorgrafts&#8482;, unlike standard cell line
derived xenografts, are implanted directly from primary human cancer tumors and
never passaged in cell tissue culture. Champions Biotechnology believes that
these xenografts more closely reflect human cancer biology and are more
predictive of clinical outcome. Champions Biotechnology has several patent
applications relating to xenograft models used for identifying potentially
active chemotherapeutic agents. Champions Biotechnology believes that it as well
as biotechnology and  pharmaceutical companies, as part of their drug discovery
and post marketing efforts, may benefit from utilizing services that are more
predictive and that might provide for a faster and less expensive path for drug
approval. These services will utilize Biomerk Tumorgrafts&#8482; to evaluate
tumor sensitivity/resistance to various single and combination standard and
novel chemotherapy agents.</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>2</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This press release contains
"forward-looking statements" (within the meaning of the Private Securities
Litigation Act of 1995) that inherently involve risk and uncertainties.
Champions Biotechnology generally uses words such as "believe," "may," "could,"
"will," "intend," "expect," "anticipate," "plan," and similar expressions to
identify forward-looking statements. One should not place undue reliance on
these forward-looking statements. Champions Biotechnology&#8217;s actual results
could differ materially from those anticipated in the forward-looking statements
for many unforeseen factors, which may include, but are not limited to, changes
in general economic conditions, the ongoing threat of terrorism, ability to have
access to financing sources on reasonable terms and other risks that are
described in this document. Although Champions Biotechnology believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology&#8217;s future results, levels of activity, performance
or achievements may not meet these expectations. Champions Biotechnology does
not intend to update any of the forward-looking statements after the date of
this press release to conform these statements to actual results or to changes
in Champions Biotechnology&#8217;s expectations, except as required by law. </p>
&nbsp;	<p>
Contact: James Martell (703) - 526-0400</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>3</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
